Search for dissertations about: "SIMULATIONS NONMEM"

Showing result 1 - 5 of 6 swedish dissertations containing the words SIMULATIONS NONMEM.

  2. 1. Pharmacometric Methods and Novel Models for Discrete Data

    Author : Elodie L Plan; Mats O Karlsson; Laura Sargentini-Maier; Armel Stockis; Christian Laveille; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacometrics; pharmacodynamics; disease progression; modelling; discrete data; count; ordered categorical; repeated time-to-event; RTTCE; RCEpT; NONMEM; FOCE; LAPLACE; SAEM; AGQ; pain scores; epilepsy seizures; gastroesophageal symptoms; statistical power; simulations; diagnostics; PHARMACY; FARMACI; Pharmacokinetics and Drug Therapy; Farmakokinetik och läkemedelsterapi;

    Abstract : Pharmacodynamic processes and disease progression are increasingly characterized with pharmacometric models. However, modelling options for discrete-type responses remain limited, although these response variables are commonly encountered clinical endpoints. Types of data defined as discrete data are generally ordinal, e.g. READ MORE

  4. 2. Pharmacometric Models in Anesthesia and Analgesia

    Author : Marcus Björnsson; Ulrika Simonsson; Mats Karlsson; Leonid Gibiansky; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacometrics; Anesthesia; Analgesia; Dropout; NONMEM; Pharmacokinetics and Drug Therapy; Farmakokinetik och läkemedelsterapi;

    Abstract : Modeling is a valuable tool in drug development, to support decision making, improving study design, and aid in regulatory approval and labeling. This thesis describes the development of pharmacometric models for drugs used in anesthesia and analgesia. READ MORE

  5. 3. Benefits of Pharmacometric Model-Based Design and Analysis of Clinical Trials

    Author : Kristin E Karlsson; E Niclas Jonsson; Mats O Karlsson; Anders Grahnén; Michael K Smith; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; model-based analysis; pharmacometrics; modeling; disease progression; NONMEM; SAEM; Importance sampling; repeated time-to-event; RTTCE; RCEpT; NIH stroke scale; Barthel index; internal validation; external validation; study power; study design; PHARMACY; FARMACI; Pharmacokinetics and Drug Therapy; Farmakokinetik och läkemedelsterapi;

    Abstract : Quantitative pharmacokinetic-pharmacodynamic and disease progression models are the core of the science of pharmacometrics which has been identified as one of the strategies that can make drug development more effective. To adequately develop and utilize these models one needs to carefully consider the nature of the data, choice of appropriate estimation methods, model evaluation strategies, and, most importantly, the intended use of the model. READ MORE

  6. 4. Pharmacokinetic drug-drug interactions in the management of malaria, HIV and tuberculosis

    Author : Doaa Elsherbiny; Ulrika Simonsson; Mats Karlsson; Lars Ståhle; Uppsala universitet; []
    Keywords : Pharmacokinetics Pharmacotherapy; Pharmacokinetics; Drug-drug interactions; Cytochrome P-450; Artemisinin antimalarials; Nevirapine; Lopinavir; Rifampicin; NONMEM; Farmakokinetik Farmakoterapi;

    Abstract : Malaria, Human Immunodeficiency Virus (HIV) and tuberculosis (TB) are global health problems having their worst situation in sub-Saharan Africa. Consequently, concomitant use of antimalarial, antiretroviral and antitubercular drugs may be needed, resulting in a potential risk of drug-drug interactions. READ MORE

  7. 5. Pharmacometric models in the development of biological medicinal products

    Author : Ari Brekkan; Mats Karlsson; Siv Jönsson; Philip Lowe; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacometrics; model-based analysis; NONMEM; population modelling.;

    Abstract : Biological medicinal products (BMPs) are a successful class of drugs that are indicated in numerous diseases.  Common among them is that complexities associated with their manufacture and analysis lead to a high cost compared to small-molecular weight drugs. READ MORE